巨子 ICON - 財經股票資訊及專家分析
搜尋 股票

Fennec Pharmaceuticals

FENC
最少15分鐘延遲,股票資訊由第三方資訊供應商提供
・Fennec Pharmaceuticals - 延遲價格・最後更新於 19/01 8:25
最高位
4.600
最低位
4.470
開市價
--
前收市價
4.600
成交量(千)
1.52
成交額(百萬)
0.06
買入
--
賣出
--
每手股數
--
市值(百萬)
118.07
市盈率
--
息率
--
差價
--
52週高低
10.078 - 3.822
所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

企業資料

公司名稱
Fennec Pharmaceuticals
證券代碼
FENC.US
所屬板塊
Biotechnology
公司業務
Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its lead product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children.
發行量
26002853
公司總部
68 TW Alexander Drive, P.O. Box 13628
公司網址
https://www.fennecpharma.com
公司電郵
info@fennecpharma.com
公司電話
+1 919 636-4530
暫無內容

關於

Fennec Pharmaceuticals(FENC.US)所屬的行業板塊為Biotechnology。
Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its lead product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children.
詳細公司背景可參考: https://www.fennecpharma.com